PURE Bioscience Sets Fiscal 2019 Third Quarter and Nine-Month Financial Results Call
SAN DIEGO--(BUSINESS WIRE)--May 22, 2019--
PURE Bioscience, Inc. ( OTCQB: PURE ), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that on June 13, 2019 the Company will file its Form 10-Q shortly after the close of the market and will host an investor conference call that day at 1:30pm PT (4:30pm ET) to review fiscal 2019 third quarter and nine-month financial results.
PURE management will also discuss the progress made to commercialize its two antimicrobial SDC-based food safety solutions:
- PURE Control ® - The status of ongoing sales and marketing of FDA approved processing aid (direct food contact) for fresh produce.
- PURE ® Hard Surface disinfectant - The status of ongoing commercialization in restaurant chains, processors/manufacturers, and the food transportation sanitization market.
The Participant Dial-In Number for the conference call is 1-631-891-4304. Participants should dial in to the call at least five minutes before 1:30pm PDT (4:30pm ET) on June 13, 2019. The call can also be accessed “live” online at http://public.viavid.com/index.php?id=134416.
A replay of the recorded call will be available for 90 days on the Company’s website ( http://www.purebio.com/investors/events-presentations/ ). You can also listen to a replay of the call by dialing 1-844-512-2921 (international participants dial 1-412-317-6671) starting June 13, 2019, at 7:30pm ET through June 20, 2019 at 11:59pm ET. Please use PIN Number 10006753.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release concerning the company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2018 and Form 10-Q for the second fiscal quarter ended January 31, 2019. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190522005201/en/
CONTACT: Hank Lambert, CEO
PURE Bioscience, Inc.
619-596-8600 firstname.lastname@example.orgTerri MacInnis, VP of IR
Bibicoff + MacInnis, Inc.
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MANUFACTURING CHEMICALS/PLASTICS PACKAGING RETAIL FOOD/BEVERAGE
SOURCE: PURE Bioscience, Inc.
Copyright Business Wire 2019.
PUB: 05/22/2019 08:36 AM/DISC: 05/22/2019 08:36 AM